EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trends in cancer survival in England and Wales



Trends in cancer survival in England and Wales



Lancet 353(9162): 1437-1438



The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory monitoring because of concerns about safety. Orally active direct inhibitors of thrombin and factor Xa may replace coumarins. Aspirin is of limited efficacy because it inhibits only one pathway of platelet activation. Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin and are used in the clinic.

(PDF same-day service: $19.90)

Accession: 035985254

Download citation: RISBibTeXText

PMID: 10227241

DOI: 10.1016/S0140-6736(99)03340-1



Related references

Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet. Oncology 10(4): 351-369, 2009

40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 385(9974): 1206-1218, 2015

Trends and inequalities in laryngeal cancer survival in men and women England and Wales 1991–26. 2011

Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU International 85(9): 1058-1062, June, 2000

Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clinical Oncology ) 13(6): 448-452, 2002

Cancer trends in England and Wales. Good data and analysis are vital to improving survival. Bmj 320(7239): 884-885, 2000

Trends and inequalities in laryngeal cancer survival in men and women: England and Wales 1991-2006. Oral Oncology 48(3): 284-289, 2012

Small intestinal cancer in England & Wales and Scotland: time trends in incidence, mortality and survival. Alimentary Pharmacology & Therapeutics 23(9): 1297-1306, 2006

Pancreatic cancer in England and Wales 1975-2000: patterns and trends in incidence, survival and mortality. Alimentary Pharmacology & Therapeutics 23(8): 1205-1214, 2006

Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Alimentary Pharmacology & Therapeutics 17(5): 655-664, 1st March, 2003

Survival trends for small intestinal cancer in England and Wales, 1971-1990: national population-based study. British Journal of Cancer 95(9): 1296-1300, 2006

Trends in prevalence and survival of very low birthweight infants, England and Wales: 1983-7. Archives of Disease in Childhood 66(11): 1304-1308, 1991